دورية أكاديمية
Influence of Pre-treatment Saliva Microbial Diversity and Composition on Nasopharyngeal Carcinoma Prognosis.
| العنوان: | Influence of Pre-treatment Saliva Microbial Diversity and Composition on Nasopharyngeal Carcinoma Prognosis. |
|---|---|
| المؤلفون: | Du Y; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Feng R; Department of Epidemiology and Health Statistics and Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China., Chang ET; Exponent, Inc., Center for Health Sciences, Menlo Park, CA, United States., Debelius JW; Centre for Translational Microbiome Research, Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Solna, Sweden.; Karolinska Institutet, Science for Life Laboratory, Solna, Sweden., Yin L; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Xu M; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang T; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.; Radiation Oncology Clinical Medical Research of Guangxi Medical University, Nanning, China., Zhou X; Life Science Institute, Guangxi Medical University, Nanning, China.; Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Nanning, China., Xiao X; Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China., Li Y; Guangxi Health Commission Key Laboratory of Molecular Epidemiology of Nasopharyngeal Carcinoma, Wuzhou Red Cross Hospital, Wuzhou, China., Liao J; Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention, Wuzhou, China., Zheng Y; Guangxi Health Commission Key Laboratory of Molecular Epidemiology of Nasopharyngeal Carcinoma, Wuzhou Red Cross Hospital, Wuzhou, China., Huang G; Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China., Adami HO; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.; Clinical Effectiveness Research Group, Institute of Health, University of Oslo, Oslo, Norway.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, United States., Zhang Z; Department of Otolaryngology-Head & Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China., Cai Y; Guangxi Health Commission Key Laboratory of Molecular Epidemiology of Nasopharyngeal Carcinoma, Wuzhou Red Cross Hospital, Wuzhou, China., Ye W; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2022 Mar 22; Vol. 12, pp. 831409. Date of Electronic Publication: 2022 Mar 22 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Nasopharyngeal Neoplasms*/microbiology , Saliva*/microbiology, Humans ; Nasopharyngeal Carcinoma ; Phylogeny ; RNA, Ribosomal, 16S/genetics |
| مستخلص: | Background: The human microbiome has been reported to mediate the response to anticancer therapies. However, research about the influence of the oral microbiome on nasopharyngeal carcinoma (NPC) survival is lacking. We aimed to explore the effect of oral microbiota on NPC prognosis. Methods: Four hundred eighty-two population-based NPC cases in southern China between 2010 and 2013 were followed for survival, and their saliva samples were profiled using 16s rRNA sequencing. We analyzed associations of the oral microbiome diversity with mortality from all causes and NPC. Results: Within- and between-community diversities of saliva were associated with mortality with an average of 5.29 years follow-up. Lower Faith's phylogenetic diversity was related to higher all-cause mortality [adjusted hazard ratio (aHR), 1.52 (95% confidence interval (CI), 1.06-2.17)] and NPC-specific mortality [aHR, 1.57 (95% CI, 1.07-2.29)], compared with medium diversity, but higher phylogenetic diversity was not protective. The third principal coordinate (PC3) identified from principal coordinates analysis (PCoA) on Bray-Curtis distance was marginally associated with reduced all-cause mortality [aHR, 0.85 (95% CI, 0.73-1.00)], as was the first principal coordinate (PC1) from PCoA on weighted UniFrac [aHR, 0.86 (95% CI, 0.74-1.00)], but neither was associated with NPC-specific mortality. PC3 from robust principal components analysis was associated with lower all-cause and NPC-specific mortalities, with HRs of 0.72 (95% CI, 0.61-0.85) and 0.71 (95% CI, 0.60-0.85), respectively. Conclusions: Oral microbiome may be an explanatory factor for NPC prognosis. Lower within-community diversity was associated with higher mortality, and certain measures of between-community diversity were related to mortality. Specifically, candidate bacteria were not related to mortality, suggesting that observed associations may be due to global patterns rather than particular pathogens. Competing Interests: Author EC was employed by Exponent, Inc., Center for Health Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Du, Feng, Chang, Debelius, Yin, Xu, Huang, Zhou, Xiao, Li, Liao, Zheng, Huang, Adami, Zhang, Cai and Ye.) |
| References: | Lancet Glob Health. 2016 Sep;4(9):e609-16. (PMID: 27470177) Cell Host Microbe. 2017 Nov 8;22(5):589-599. (PMID: 29120742) Int Immunopharmacol. 2020 Nov;88:106876. (PMID: 32799113) mSystems. 2019 Feb 12;4(1):. (PMID: 30801021) Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):731-740. (PMID: 30733306) mSystems. 2020 Jul 7;5(4):. (PMID: 32636333) Brief Bioinform. 2019 Jan 18;20(1):210-221. (PMID: 28968702) Radiother Oncol. 2018 Oct;129(1):44-51. (PMID: 29735410) mBio. 2015 Nov 10;6(6):e01693-15. (PMID: 26556275) JDR Clin Trans Res. 2018 Jan;3(1):57-64. (PMID: 29662960) Anal Biochem. 2006 Jun 15;353(2):272-7. (PMID: 16620753) Science. 2017 Sep 15;357(6356):1156-1160. (PMID: 28912244) Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288) Clin Cancer Res. 2019 Oct 15;25(20):6170-6179. (PMID: 31358543) Cell. 2019 Aug 8;178(4):795-806.e12. (PMID: 31398337) Radiat Oncol. 2015 Jun 30;10:136. (PMID: 26122711) Immunology. 2016 Jan;147(1):1-10. (PMID: 26439191) Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151) Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047. (PMID: 33849968) Microb Ecol. 2015 Feb;69(2):434-43. (PMID: 25524570) Nat Commun. 2019 Jun 20;10(1):2719. (PMID: 31222023) Clin Cancer Res. 2016 Nov 15;22(22):5574-5581. (PMID: 27769987) Oncotarget. 2017 Jul 29;8(50):87073-87085. (PMID: 29152064) Sci Rep. 2016 Jan 18;6:19290. (PMID: 26776301) mSystems. 2017 Feb 21;2(1):. (PMID: 28251186) Nat Med. 2018 Oct;24(10):1532-1535. (PMID: 30150716) Biomed Res Int. 2017;2017:8106491. (PMID: 29082256) Commun Biol. 2021 Feb 22;4(1):237. (PMID: 33619320) Lancet Oncol. 2018 Mar;19(3):382-393. (PMID: 29428165) Arch Oral Biol. 2014 Feb;59(2):176-86. (PMID: 24370189) Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029) ISME J. 2016 Oct;10(10):2435-46. (PMID: 27015003) Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):145-150. (PMID: 32866565) Chin Clin Oncol. 2016 Apr;5(2):16. (PMID: 27121876) Turk J Med Sci. 2019 Mar 13;49(2):558-565. (PMID: 30862133) Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):579-588. (PMID: 29195678) Microbiome. 2017 Feb 8;5(1):17. (PMID: 28179014) Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2285-94. (PMID: 24252872) Cancer. 2006 Jan 15;106(2):329-36. (PMID: 16342066) Oncotarget. 2015 Mar 30;6(9):7209-20. (PMID: 25797243) EBioMedicine. 2017 Apr;18:23-31. (PMID: 28216066) Gastroenterology. 2018 Aug;155(2):529-541.e5. (PMID: 29689266) Int J Cancer. 2019 Nov 15;145(10):2873-2883. (PMID: 31044420) BMC Cancer. 2020 May 6;20(1):383. (PMID: 32375706) |
| فهرسة مساهمة: | Keywords: 16S rRNA sequencing; diversity; nasopharyngeal carcinoma; oral microbiome; prognosis |
| المشرفين على المادة: | 0 (RNA, Ribosomal, 16S) |
| تواريخ الأحداث: | Date Created: 20220408 Date Completed: 20220411 Latest Revision: 20220607 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8981580 |
| DOI: | 10.3389/fcimb.2022.831409 |
| PMID: | 35392614 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2022.831409 |